|
|
Viatris Inc (NASDAQ: VTRS) |
|
Price: $11.3000
$-0.04 
-0.353%
|
| Day's High:
| $11.475
| Week Perf:
| -4.24 %
|
| Day's Low: |
$ 11.23 |
30 Day Perf: |
-9.82 % |
| Volume (M): |
7,724 |
52 Wk High: |
$ 13.62 |
| Volume (M$): |
$ 87,277 |
52 Wk Avg: |
$11.71 |
| Open: |
$11.34 |
52 Wk Low: |
$9.93 |
|
|
| Market Capitalization (Millions $) |
13,565 |
| Shares
Outstanding (Millions) |
1,200 |
| Employees |
38,000 |
| Revenues (TTM) (Millions $) |
15,049 |
| Net Income (TTM) (Millions $) |
-883 |
| Cash Flow (TTM) (Millions $) |
568 |
| Capital Exp. (TTM) (Millions $) |
351 |
Viatris Inc
Viatris Inc. is a global pharmaceutical company focused on providing affordable access to high-quality medicines for patients worldwide. The company was formed as a result of the merger between Mylan N.V. and Pfizeres Upjohn business in November 2020. Headquartered in Pittsburgh, Pennsylvania, Viatris has operations in more than 165 countries, and its medicines are used by more than one billion people globally.
The company has a diverse portfolio of products that span across various therapeutic areas such as cardiovascular, central nervous system, dermatology, gastroenterology, HIV/AIDS, and oncology. Some of its well-known brands include Lipitor, Advil, Celebrex, and Viagra.
Viatris employs more than 45,000 people worldwide and has a strong commitment to sustainability and corporate social responsibility. The company strives to reduce its environmental footprint by promoting responsible manufacturing practices, sourcing renewable energy, and reducing water usage.
In terms of financials, Viatris had revenues of $11.9 billion in 2020, and its products are sold in more than 165 countries worldwide. The company's market capitalization as of August 2021 is approximately $15 billion.
Viatris leadership is committed to driving growth and innovation by investing in its portfolio, technology, and partnerships with other companies. The company's leadership team is composed of experienced executives with extensive experience in the pharmaceutical industry, including Heather Bresch, CEO, and Rajiv Malik, President.
Overall, Viatris is a global pharmaceutical company focused on delivering high-quality medicines at affordable prices to patients worldwide. The company's diverse portfolio of products, global reach, commitment to sustainability, and strong leadership all contribute to its success and continued growth.
Company Address: 1000 Mylan Boulevard Canonsburg 15317 PA
Company Phone Number: 514-1800 Stock Exchange / Ticker: NASDAQ VTRS
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Viatris Inc
Financial news report:
Viatris Inc. (NASDAQ: VTRS), a global healthcare company, recently reported a significant decline in earnings per share and revenue for the January to March 31, 2024 period compared to the same period last year. The company's earnings per share decreased by -52.63% to $0.09, while revenue experienced a decrease of -1.762% to $3.66 billion.
In contrast, the overall Major Pharmaceutical Preparations sector saw a 2.72% growth in revenue during the same quarter, compared to the first quarter of 2023. However, Viatris Inc.'s performance did not align with this positive trend. In the previous reporting period, the company's earnings per share were at a negative $-0.97 per share, while revenue experienced a decline of -4.532% to $3.84 billion.
|
| Personnel Announcements
Published Mon, Apr 15 2024 12:00 PM UTC
PITTSBURGH, April 15, 2024 - Viatris Inc. (NASDAQ: VTRS), a global healthcare company, announced today the appointment of Corinne Le Goff as Chief Commercial Officer. Le Goff will also join the esteemed Executive Leadership Team of the company, effective immediately. This strategic move aims to leverage Le Goff s extensive industry experience and expertise, positioning ...
|
| Viatris Inc
Viatris Inc: A Promising Turnaround Story
Viatris Inc, a major player in the pharmaceutical industry, recently released its financial results for the fiscal period ending December 31, 2023. While the numbers may initially appear disappointing, a closer look reveals a company that is taking strategic steps to improve its financial position and set itself up for a strong future.
During the fiscal period, Viatris slipped into a deficit of $0.97 per share, compared to earnings of $0.82 per share in the previous year. Additionally, the company saw a decrease in revenue by 0.998%, with a total of $3.84 billion for the period. The net deficit for the period amounted to $765.6 million, a significant drop from the $1,011.2 million profit in the previous year.
|
| Personnel Announcements
Published Fri, Dec 15 2023 9:45 PM UTC
PITTSBURGH, Dec. 15, 2023 - Viatris Inc. (NASDAQ: VTRS), a global healthcare company, publicly disclosed its preparations for Phase 2 of its strategic plan by appointing Theodora Doretta Mistras as Chief Financial Officer and Philippe Martin as Chief R&D Officer. Mistras is set to assume the role on March 1, 2024, joining Viatris after a successful career in the finance...
|
| Viatris Inc
Viatris Inc, a major player in the pharmaceutical preparations industry, has witnessed contrasting trends in its stock performance. While the stock declined by -4.33% during the preceding month, it saw a 4.86% increase in the past five trading days. The company also traded 6.1% above its 52-week low. However, these positive stock movements come in the backdrop of soft financial results reported by Viatris Inc for the financial period closing on September 30, 2023. This article will explore the implications of these contrasting factors on the company's future.
1. Revenue and Profitability:
Viatris Inc faced a revenue decline of -3.342% year-on-year, with revenues decreasing to $3.94 billion. This presents a concerning trend compared to other players in the Major Pharmaceutical Preparations industry, who reported revenue gains for the same period. Furthermore, the bottom-line (net income) of Viatris Inc also experienced a significant setback, dropping by -6.9% to $0.27 per share. Profitability indicators such as operating margin and net margin also saw reductions, indicating potential challenges ahead.
|
| Per Share |
Current |
| Earnings (TTM) |
-1.07 $ |
| Revenues (TTM) |
12.54 $
|
| Cash Flow (TTM) |
0.47 $ |
| Cash |
1.57 $
|
| Book Value |
16.49 $
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
-1.07 $
|
| Revenues (TTM) |
12.54 $ |
| Cash Flow (TTM) |
0.47 $ |
| Cash |
1.57 $
|
| Book Value |
16.49 $ |
| Dividend (TTM) |
0 $ |
|
|
| |
| Brands |
|
 62.97 % |
of total Revenue |
| Generics |
|
36.68 % |
of total Revenue |
| Lipitor |
|
10.01 % |
of total Revenue |
| Norvasc |
|
4.5 % |
of total Revenue |
| Lyrica |
|
3.46 % |
of total Revenue |
| EpiPen Auto-Injectors |
|
3.28 % |
of total Revenue |
| Viagra |
|
2.67 % |
of total Revenue |
| Creon |
|
2.26 % |
of total Revenue |
| Celebrex |
|
1.98 % |
of total Revenue |
| Effexor |
|
1.77 % |
of total Revenue |
| Zoloft |
|
1.62 % |
of total Revenue |
| Xalabrands |
|
1.1 % |
of total Revenue |
| Influvac |
|
3.23 % |
of total Revenue |
| Yupelri |
|
1.66 % |
of total Revenue |
| Dymista |
|
1.16 % |
of total Revenue |
| Xanax |
|
1.03 % |
of total Revenue |
| Amitiza |
|
1.02 % |
of total Revenue |
| Developed Markets Brands |
|
32.46 % |
of total Revenue |
| Developed Markets Generics |
|
28.82 % |
of total Revenue |
| Greater China Brands |
|
14.91 % |
of total Revenue |
| Greater China Generics |
|
0.06 % |
of total Revenue |
| Japan Australia and New Zealand Brands |
|
5.05 % |
of total Revenue |
| Japan Australia and New Zealand Generics |
|
4.13 % |
of total Revenue |
| Emerging Markets Brands |
|
10.55 % |
of total Revenue |
| Emerging Markets Generics |
|
3.66 % |
of total Revenue |
| Developed Markets Segment |
|
61.28 % |
of total Revenue |
| Greater China |
|
14.98 % |
of total Revenue |
| Japan Australia and New Zealand Segment |
|
9.18 % |
of total Revenue |
| Emerging Markets Segment |
|
14.21 % |
of total Revenue |
| Greater China Segment |
|
14.98 % |
of total Revenue |
|
|
0.26%